Patent · US Active

Modified oligonucleotides for use in treatment of tauopathies

US11453881B2 · kind B2 · utility

0Cited by

0References

32Claims

0Family size

Assignee

Janssen Pharmaceuticals, Inc. · BE

Inventors

Andreas Ebneth · Turnhout, BE
Constantin Van Outryve d'Ydewalle · Baltimore, US
Sergei Gryaznov · San Mateo, US
Saul Martinez Montero · San Bruno, US
Leonid Beigelman · San Mateo, US
Vivek Kumar Rajwanshi · Cupertino, US

Key dates

Filing date	Mar 13, 2019
Grant date	Sep 27, 2022
Priority date	—
Expiry date	May 19, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/50
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Oligonucleotides comprising modifications at the 2′ and/or 3′ positions(s) along with methods of making and use against Alzheimer disease and other tauopathies are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.